Skip to main content

Table 3 Anti-topoisomerase I antibody-positive versus antibody-negative patients in systemic sclerosis cohort assessed by line immunoblot assay

From: Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort

Disease manifestation Patients with disease manifestation Anti-topoisomerase I P value Sensitivity (%) Specificity (%)
   Positive (n = 67) Negative (n = 213)    
Digital ulcers 112 (40.0%) 38 (56.7%) 74 (34.7%) 0.002 33.9 82.7
Lung fibrosis 98 (35.0%) 46 (68.6%) 52 (24.4%) <0.0005 46.9 88.5
DLCO by a single breath   62.9 ± 20.8 72.9 ± 19.9 <0.0005 NA NA
Mean FVC   81.1 ± 18.0 91.8 ± 18.7 <0.0005 NA NA
Pulmonary arterial hypertension 60 (21.4%) 17 (25.4%) 43 (20.2%) 0.39 28.3 77.3
Contractures 162 (57.9%) 59 (88.1%) 113 (53.1%) <0.0005 34.3 92.6
Renal involvement 56 (20.0%) 13 (19.4%) 43 (20.2%) 1 23.2 75.9
Renal crisis 16 (5.7%) 6 (9%) 10 (4.7%) 0.23 37.5 76.8
Cardiac involvement 114 (40.7%) 33 (49.2%) 81 (38.0%) 0.12 28.9 79.5
Conduction blocks 69 (24.6%) 25 (37.3%) 44 (20.7%) 0.009 36.2 80.1
Electrocardiogram changes 74 (26.4%) 27 (40.3%) 47 (22.1%) 0.007 36.5 80.4
mRSS   14.2 ± 10.2 5.57 ± 5.8 <0.0005 NA NA
Raynaud's phenomenon 272 (97.1%) 67 (100%) 205 (96.2%) 0.2 24.6 100
Diffuse systemic sclerosis 96 (34.3%) 58 (86.6%) 38 (17.8%) <0.0005 60.4 95.1
Mean disease activity   2.49 1.63 <0.0005 NA NA
  1. Data presented as n (%) or mean ± standard deviation. DLCO, predicted diffusion capacity; FVC, predicted forced vital capacity; mRSS, modified Rodnan skin score; NA, not applicable.